| Literature DB >> 30678426 |
Yi Sun1, Huang Xiaoyan, Liu Yun, Liu Chaoqun, Wen Jialing, Yang Liu, Zhao Yingqi, Yi Peipei, Peng Junjun, Lu Yuanming.
Abstract
Ovarian cancer is one of the three major gynecologic cancers in the world. The aim of this study is to find the relationship between ovarian cancer and diabetes mellitus by using the genetic screening technique. By GEO database query and related online tools of analysis, we analyzed 185 cases of ovarian cancer and 10 control samples from GSE26712, and a total of 379 different genes were identified, including 104 up-regulated genes and 275 down-regulated genes. The up-regulated genes were mainly enriched in biological processes, including cell adhesion, transcription of nucleic acid and biosynthesis, and negative regulation of cell metabolism. The down-regulated genes were enriched in cell proliferation, migration, angiogenesis and macromolecular metabolism. Protein-protein interaction was analyzed by network diagram and module synthesis analysis. The top ten hub genes (CDC20, H2AFX, ENO1, ACTB, ISG15, KAT2B, HNRNPD, YWHAE, GJA1 and CAV1) were identified, which play important roles in critical signaling pathways that regulate the process of oxidation-reduction reaction and carboxylic acid metabolism. CTD analysis showed that the hub genes were involved in 1,128 distinct diseases (bonferroni-corrected P<0.05). Further analysis by drawing the Kaplan-Meier survival curve indicated that CDC20 and ISG15 were statistically significant (P<0.05). In conclusion, glycometabolism was related to ovarian cancer and genes and proteins in glycometabolism could serve as potential targets in ovarian cancer treatment. Creative Commons Attribution LicenseEntities:
Keywords: Bioinformatics analysis; microarray; ovarian cancer; diabetes mellitus
Mesh:
Year: 2019 PMID: 30678426 PMCID: PMC6485580 DOI: 10.31557/APJCP.2019.20.1.145
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Identification of the Up-Regulated and Down-Regulated Differential Genes
| DEGs | Genes Name |
|---|---|
| Up-regulated | CD24 CD24 SNORA68 RPL18A CD24 CLDN3 IGFBP2 LOC101929219 LOC100505650 C1orf186 HIST2H2AA4 HIST2H2AA3 CALR WFDC2 SCGB2A1 FOLR1 CD24 PFN1 CRABP2 |
| PKM COL1A1 RPL37ASOX17 RPS7 CD24 PPDPF MUC1 MECOM C9orf16 NOTCH3 CLDN3 ACTB RHOB S100A13 ELF3 LCN2 SLC52A2 IGLC1 KLK6 S100A11 DEFB1 | |
| INS-IGF2 IGF2 HMGA1 ISG15 FOLR1 GSTP1 TAGLN S100A2 H2BFS IGLC1 CALR COL1A1 CKS2 CP IGHA2 IGHA1 IGH ATP5H H2AFX YWHAE PEA15 ADGRG1 PRMT1 | |
| S100A6 LSM4 SOX9 MMP11 SETSIP SETP4 SET CYAT1 IGLV1-44 IGLC1 PRKCSH MIR7113 MIR4691 NDUFS8 CL2L2-PABPN1 PABPN1 C9orf16 GRINA LOC100506248 | |
| MIR1244-2 MIR1244-3 MIR1244-1 LOC728026 PTMA MMP7 ACTB NT5DC2 BCAM COL6A2 FXYD3 JUNB MUC1 PAX8 UBE2C CLDN4 LYPD1 UQCRQ HSPG2 MRPS12 | |
| ZNF593 CDC20 IGLV1-44 C1orf106 IDH2 IFI6 ENO1 COX7B SLC39A4 IFI27 KLK8 KDELR1 MDK HIST1H1C UCP2 MIR1282 HYPK SERF2 TMED2 PRSS8 ATP2A2 BCAM | |
| CHMP5 PAXBP1 EZR MEF2C SCP2 RARRES1 PLIN2 HSD17B11 PRNP DCUN1D4 HAS1 DLG5 EPS15 PNRC2 PDZD2 ATF1 ADGRG6 CPE BAMBI PRKAR1A GJA1 NR2F2 | |
| RSRP1 PLCB1 CHMP2B VPS13C TJP2 ADH5 NEFH CAV2 ANK3 SMARCA2 CHGB ZNF45 RARRES1 RHOT1 LIPA EFHC1 ATMIN PURA GLS WT1 SFRP1 C21orf62 | |
| LOC101929500 CRIM1 KAT2B BICC1 SERPINB9 ADAMTS3 PRKAR2B GALNT12 PDPN HNRNPD GNG11 TOB1 SEL1L3 DCN GPR137B ISOC1 MAP3K8 TSPYL1 SNX7 UPK3B | |
| CIRBP PREPL PTPRC NT5C1B-RDH14 RDH14 CLK1 PODXL SNORD45C SNORD45A SNORD45B RABGGTB HPR HP CELF2 ANOS1 LGALS2 PCDH9 PKD2 ARAP2 CELF2 | |
| CAV2 KLF4 PCOLCE2 PLCE1 LUC7L3 ARHGAP44 LAMB1 FZD7 SLC16A1 PRKAR1A ARHGAP6 GFPT2 DAPK1 FZD7 CLDN15 S100PBP ACSL1 ZDHHC17 DSC3 ADAM9 | |
| FLRT3 SEMA5A ITGAM CFH PGRMC2 SOBP GABARAPL3 GABARAPL1 PSD3 TSPAN8 ATP10D ME1 ZBTB20 IGFBP6 RBM25 WSB1 RAP2C TCF21 PTGER3 GPRASP1 | |
| CSGALNACT1 SLK GCOM1 POLR2M ATP8A1 GALC GCA TSPAN13 ATXN1 CFHR1 CFH DOCK4MIR22 MIR22HG OGN UFSP2 TLE4 RECK SARAF FEZ2 SMARCA2 | |
| Down-regulated | TPD52L1 PDGFC PDE8B GSAP GSAP HBA2 HBA1 FGF9 PHACTR2 PNISR CREBL2 CPVL SLC46A3 OLFML1 HBG2 HBG1 MTUS1 CLEC4M TRPC1 LXN CAST CLEC4M HBA2 |
| BA1 GHR CPE SEMA3C SULF1 HBA2 HBA1 DPYSL2 TACC1 SLC16A1 NSG1 METTL7A ECM2 QKI HBA2 HBA1 NKX3-1 CFI CLIC5 PTGIS LOC101926921 DAB2 RARRES1 | |
| DMD HOXC6 WNT2B ZNF330 PTGER4 NR2F1 GREB1 SNCAIP MARCO GAS1 LAMA4 FRMD4B AQP9 IL6ST BTAF1 HP SCG5 ZFPM2 FGF13 FAM13B RSRP1 DIRAS3 | |
| ALDH1A1 WNT5A TMX4 AMIGO2 ANXA3 CREBL2 ID4 N4BP2L2 GATA6 RGS4 CAV1 HBA2 HBA1 DDX17 LOC101926921 DAB2 TFPI2 PLPP1 RNASE4 RTN1 PRG4 HBB | |
| REEP1 PDGFD MEIS2 TFPI2 DSE FRY KDR HEG1 HBB PEG3 SFRP1 MAF SPOCK1 MET LGALS8 NAP1L3 PSD3 TMEM255A DFNA5 PROS1 LGALS8 PLSCR4 ANXA8L1 | |
| ANXA8 ARMCX1 PROCR ADH1B HBA2 HBA1 CHRDL1 SLC39A8 ADH1B SLC4A4NPY1R NELL2 DPYD BNC1 LHX2 GPM6A EFEMP1 CALB2 REEP1 STK26 OC100506718 | |
| FLRT2 TCEAL2 HB ABCA8 EFEMP1 AOX1 LOC101928635 ALDH1A2 BCHE MNDA LOC101930363 LOC101928349 LOC100507387 FAM153C FAM153A FAM153B |
Figure 1Heat Map of the Top Differentially Expressed Genes (50 up- and 50 down-regulated genes). Red, up-regulation; Blue, down-regulation
Figure 2Gene Ontology Anlysis; A, Significantly enriched GO terms of DEGs in ovarian cancer; B, Significantly enriched pathway terms of DEGs in ovarian cancer
Gene Ontology Analysis of Differentially Expressed Genes Associated with Ovarian Cancer3.3 Signal Path Enrichment Analyses
| Expression | Category | Term | Count % | P- Value |
|---|---|---|---|---|
| Up-reulated | ||||
| GOTERM_BP_FAT | GO:0007399~nervous system development | 25 | 27.47252747 | 5.33E-05 |
| GOTERM_BP_FAT | GO:0007155~cell adhesion | 21 | 23.07692308 | 1.16E-04 |
| GOTERM_BP_FAT | GO:0022610~biological adhesion | 21 | 23.07692308 | 1.22E-04 |
| GOTERM_BP_FAT | GO:1901700~response to oxygen-containing compound | 19 | 20.87912088 | 1.64E-04 |
| GOTERM_BP_FAT | GO:0033993~response to lipid | 14 | 15.38461538 | 2.15E-04 |
| GOTERM_BP_FAT | GO:0045892~negative regulation of transcription, DNA-templated | 16 | 17.58241758 | 2.77E-04 |
| GOTERM_BP_FAT | GO:0010558~negative regulation of macromolecule biosynthetic process | 18 | 19.78021978 | 3.42E-04 |
| GOTERM_BP_FAT | GO:1903507~negative regulation of nucleic acid-templated transcription | 16 | 17.58241758 | 4.28E-04 |
| GOTERM_BP_FAT | GO:0010605~negative regulation of macromolecule metabolic process | 24 | 26.37362637 | 4.34E-04 |
| GOTERM_BP_FAT | GO:0031324~negative regulation of cellular metabolic process | 24 | 26.37362637 | 4.88E-04 |
| GOTERM_BP_FAT | GO:0009890~negative regulation of biosynthetic process | 18 | 19.78021978 | 6.74E-04 |
| GOTERM_BP_FAT | GO:0010033~response to organic substance | 26 | 28.57142857 | 0.0011882 |
| GOTERM_BP_FAT | GO:0009892~negative regulation of metabolic process | 24 | 26.37362637 | 0.001356973 |
| GOTERM_BP_FAT | GO:0023051~regulation of signaling | 27 | 29.67032967 | 0.00178692 |
| GOTERM_BP_FAT | GO:0010604~positive regulation of macromolecule metabolic process | 25 | 27.47252747 | 0.003192651 |
| Down-regulated | ||||
| GOTERM_BP_FAT | GO:0040011~locomotion | 48 | 21.33333333 | 5.62E-09 |
| GOTERM_BP_FAT | GO:0008283~cell proliferation | 53 | 23.55555556 | 1.77E-08 |
| GOTERM_BP_FAT | GO:0006928~movement of cell or subcellular component | 51 | 22.66666667 | 4.02E-08 |
| GOTERM_BP_FAT | GO:0016477~cell migration | 38 | 16.88888889 | 2.14E-07 |
| GOTERM_BP_FAT | GO:0032268~regulation of cellular protein metabolic process | 56 | 24.88888889 | 2.11E-06 |
| GOTERM_BP_FAT | GO:0007399~nervous system development | 52 | 23.11111111 | 5.25E-06 |
| GOTERM_BP_FAT | GO:0010604~positive regulation of macromolecule metabolic process | 62 | 27.55555556 | 1.04E-05 |
| GOTERM_BP_FAT | GO:0010605~negative regulation of macromolecule metabolic process | 53 | 23.55555556 | 1.72E-05 |
| GOTERM_BP_FAT | GO:0009605~response to external stimulus | 48 | 21.33333333 | 3.47E-05 |
| GOTERM_BP_FAT | GO:0050790~regulation of catalytic activity | 52 | 23.11111111 | 5.13E-05 |
| GOTERM_BP_FAT | GO:0048514~blood vessel morphogenesis | 19 | 8.444444444 | 4.92E-05 |
| GOTERM_BP_FAT | GO:0072358~cardiovascular system development | 33 | 14.66666667 | 2.77E-07 |
| GOTERM_BP_FAT | GO:0008285~negative regulation of cell proliferation | 25 | 11.11111111 | 2.34E-06 |
| GOTERM_BP_FAT | GO:0060537~muscle tissue development | 18 | 8 | 4.03E-06 |
| GOTERM_BP_FAT | GO:0007155~cell adhesion | 43 | 19.11111111 | 1.33E-05 |
Figure 3DEGs Protein-Protein Interaction (PPI) Network Complex and Modular Analysis
Significantly Enriched Pathway Terms of DEGs in Ovarian Cancer
| Significant Enriched Pathway terms | P-Value |
|---|---|
| PI3K-Akt signaling pathway |HAS-04151 | 0.037083032 |
| Wnt signaling pathway |HAS-04310 | 0.035010312 |
| Ras signaling pathway |HAS-04014 | 0.02893891 |
| Rap1 signaling pathway |HAS-04015 | 0.001684852 |
KEGG Pathway Analysis of Differentially Expressed Genes Associated with Ovarian Cancer
| Pathway | Name | Gene | % | P Value | Genes ID |
|---|---|---|---|---|---|
| Up-reulated | DEGs | ||||
| hsa01230:Biosynthesis of amino acid | 3 | 3.296703297 | 0.074028877 | IDH2, ENO1, PKM | |
| hsa05010:Alzheimer’s disease | 4 | 4.395604396 | ATP2A2, ATP5H , UQCRQ , COX7B | ||
| hsa04512:ECM-receptor interaction | 3 | 3.296703297 | 0.097658172 | COL1A1, COL1A1, HSPG2, COL6A2 | |
| Down-reulated | DEGS | ||||
| hsa05205:Proteoglycans in cancer | 11 | 4.888888889 | 2.75E-04 | WNT5A, CAV2, CAV1, PLCE1, EZR, ANK3, MET, DCN, FZD7, KDR, WNT2B | |
| hsa04015:Rap1 signaling pathway | 10 | 4.444444444 | 0.001684852 | PLCE1, FGF9, MET, FGF13, PDGFC, PDGFD, PLCB1, ITGAM, KDR, DOCK4 | |
| hsa05200:Pathways in cancer | 14 | 6.222222222 | 0.001775521 | WNT5A, PTGER3, PTGER4, FGF9, MET, GNG11, FGF13, FZD7, DAPK1, WNT2B,LAMA4, KX3-1, LAMB1, PLCB1 | |
Pathway Enrichment Analysis of Module Agenes Function
| Gene Set | FDR | Node |
|---|---|---|
| positive regulation of biological process | 0.00364 | ACTB,ALDH1A1,BUB1,CALR,CCNB1,CDC16,CDC23,CDC27,CDK1,DD |
| X17,H2AFX,HNRNPD,ISG15,KAT2B,MAD2L1,PFN1,YWHAE | ||
| ALDH1A1,BUB1,BUB1B,CALR,CDC16,CDC20,CDC23,CDC27,CDK1,D | ||
| regulation of metabolic process | 0.016 | DX17,ENO1,EZR,GJA1,H2AFX,ISG15,KAT2B,MAD2L1,YWHAE |
| ACTB,ALDH1A1,BUB1,CALR,CDC16,CDC20,CDC23,CDC27,CDK1,DD | ||
| cellular metabolic process | 0.0487 | X17,DPYD,ENO1,EZR,H2AFX,HAS1,HNRNPD,IDH2,KAT2B,MAD2L1, |
| YWHAE |
Pathway Enrichment Analysis of Module C Genes Function
| Gene Set | FDR | Node |
|---|---|---|
| oxidation-reduction process | 7.86E-12 | ALDH1A1,DPYD,ENO1,ENO2,ENO3,GAPDH,IDH2,PGK1,PKLR,PKM,TPI1 |
| generation of precursor metabolites and energy | 2.45E-11 | ENO1,ENO2,ENO3,GAPDH,IDH2,PGK1,PKLR,PKM,TPI1 |
| nucleoside metabolic process | 2.75E-10 | DPYD,ENO1,ENO2,ENO3,GAPDH,PGK1,TPI1,UMPS |
The Relationship between Hub Gene with Ovarian Cancer or Metabolic Disease of the Comparative Toxicogenomics Database Prediction
| Hube Gene | Disease cantegories (p-value) | |||
|---|---|---|---|---|
| OC | Diabetes Mellitus, Type 1 | Diabetes Mellitus, Type 2 | Hypertriglyceridemia | |
| CDC20 | 2.22E-09 | 1.56E-38 | 3.37E-98 | 5.93E-11 |
| H2AFX | 2.14E-09 | 1.32E-38 | 2.17E-98 | 5.67E-11 |
| ENO1 | 2.24E-09 | 1.62E-38 | 3.69E-98 | 5.98E-11 |
| ACTB | - | 4.35E-35 | 1.21E-92 | 5.07E-11 |
| ISG15 | 2.20E-09 | 1.49E-38 | 2.97E-98 | 5.85E-11 |
| KAT2B | 2.12E-09 | 1.27E-38 | 1.95E-98 | 5.60E-11 |
| HNRNPD | 2.15E-09 | 1.35E-38 | 2.30E-98 | 5.70E-11 |
| YWHAE | 1.88E-09 | 7.51E-39 | 4.88E-99 | 3.35E-09 |
| GJA1 | 2.10E-09 | 1.23E-38 | 1.78E-98 | 5.55E-11 |
| CAV1 | 2.12E-09 | 1.27E-38 | 1.95E-98 | 5.60E-11 |
-, means No available data
Figure 4K-M Cures of the Top 10 Hub Genes in OC. Red line represents high level of a hub gene, and green line represents low level. These genes were statistically significant. The X axis indicates overall survival time (day), and the Y axis indicates the survival rate.
Pathway Enrichment Analysis of Module B Genes Function
| Gene Set | FDR | Node |
|---|---|---|
| oxidation-reduction process | 5.82E-10 | ALDH1A1,DPYD,ENO1,ENO2,ENO3,GAPDH,IDH2,PGK1,PKLR,PKM,TPI1 |
| Carboxylic acid metabolic process | 2.87E-09 | CAD,DPYD,DPYS,ENO1,ENO2,ENO3,GAPDH,IDH2,PGK1,TPI1 |
| single-organism catabolic process | 7.08E-09 | DPYD,DPYS,ENO1,ENO2,ENO3,GAPDH,PGK1,PKLR,PKM,TPI1 |